Axcella Hopes Interim NASH Data Can Help Extend Its Financial Runway

 
• By Joseph Haas

Axcella’s AXA1125, a therapeutic combination of amino acids, shows liver stiffness, liver enzyme and fat reduction benefits in Phase IIb interim look, but the firm lacks the cash to complete the trial.

NASH liver
Axcella uses combinations of amino acids to fight disease, including NASH • Source: Shutterstock

More from Clinical Trials

More from R&D